Concentration-dependent effects of the esterase inhibitor BNPP on macrophage migration and myelin phagocytosis.
Wallerian degeneration of a peripheral nerve is mainly characterized by axon and myelin degradation and is paralleled by a massive invasion of peripheral macrophages into the nerve. These cells enter the nerve attracted by a cascade of chemokines and cytokines but require proteolytic and enzymatic factors which enables them to cross the blood-nerve barrier. Here we investigated whether alpha-naphthyl (alpha-NA) esterases -- which have been shown to be exclusively expressed in human monocytes -- play a role during Wallerian degeneration. These enzymes were blocked by the specific inhibitor bis(4-nitrophenyl)-phosphate (BNPP) in an established in vitro model of Wallerian degeneration. Sciatic nerve segments of mice were co-cultured with peritoneal macrophages and BNPP was added to the cultures in various concentrations and at different timepoints. The macrophage numbers and myelin density in the nerve segments and the myelin load of macrophages were evaluated. After BNPP treatment the macrophage number within the nerve was significantly diminished and the myelin load within the macrophages was decreased, resulting in elevated levels of preserved myelin within the nerves. These experiments clearly showed a double effect of the alphaNA esterase inhibitor BNPP on macrophages. First, it suggests a role for alphaNA esterases on the migratory potential of macrophages since their invasion into the nerves was diminished. Second, the reduced myelin uptake is due to the inhibition of phagocytic capacity of these cells by BNPP. The therapeutical use of this inhibitor for treatment of autoimmune diseases such as multiple sclerosis or Guillain-Barré syndrome remains to be investigated.
Siebert
H
H
Institute of Neuropathology, Charité, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany.
Engelke
S
S
Maruschak
B
B
Brück
W
W
D000818:Animals; D002452:Cell Count; D002465:Cell Movement / Q000187:drug effects* / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured / Q000187:drug effects / Q000201:enzymology / Q000648:ultrastructure; D018920:Coculture Techniques; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure; D051379:Mice; D008810:Mice, Inbred C57BL; D008854:Microscopy, Electron; D009186:Myelin Sheath / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure; D009283:Naphthol AS D Esterase / Q000037:antagonists & inhibitors / Q000378:metabolism; D009596:Nitrophenols / Q000494:pharmacology*; D010525:Peripheral Nerves / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology; D010587:Phagocytosis / Q000187:drug effects* / Q000502:physiology; D012584:Sciatic Nerve / Q000187:drug effects / Q000201:enzymology / Q000503:physiopathology; D014343:Trypan Blue; D014855:Wallerian Degeneration / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology
D004791:Enzyme Inhibitors; D009596:Nitrophenols; C002887:bis(4-nitrophenyl)phosphate; D009283:Naphthol AS D Esterase; D014343:Trypan Blue